Factor H related proteins modulate complement activation on kidney cells.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
12 2022
Historique:
received: 12 09 2021
revised: 04 07 2022
accepted: 27 07 2022
pubmed: 6 9 2022
medline: 24 11 2022
entrez: 5 9 2022
Statut: ppublish

Résumé

Complement activation at a particular location is determined by the balance of activating and inhibitory proteins. Factor H is a key regulator of the alternative pathway of complement, and genetic or acquired impairments in Factor H are associated with glomerular injury. The human Factor H-related proteins (FHRs) comprise a family of five proteins that are structurally related to Factor H. Variations in the genes or expression levels of the FHRs are also associated with glomerular disease, although the mechanisms of glomerular protection/injury are incompletely understood. To explore the role of the FHRs on complement regulation/dysregulation in the kidney, we expressed and purified recombinant murine FHRs (FHRs A, B, C and E). These four distinct FHRs contain binding regions with high amino acid sequence homology to binding regions within Factor H, but we observed different interactions of the FHRs with Factor H binding ligands, including heparin and C3d. There was differential binding of the FHRs to the resident kidney cell types (mesangial, glomerular endothelial, podocytes, and tubular epithelial). All four FHRs caused complement dysregulation on kidney cell surfaces in vitro, although the magnitude of the effect differed among the FHRs and also varied among the different kidney cells. However, only FHR E caused glomerular complement dysregulation when injected in vivo but did not exacerbate injury when injected into mice with ischemic acute kidney injury, an alternative pathway-mediated model. Thus, our experiments demonstrate that the FHRs have unique, and likely context-dependent, effects on the different cell types within the kidney.

Identifiants

pubmed: 36063874
pii: S0085-2538(22)00692-5
doi: 10.1016/j.kint.2022.07.035
pmc: PMC9691546
mid: NIHMS1834437
pii:
doi:

Substances chimiques

CFH protein, human 0
Complement Factor H 80295-65-4
Complement System Proteins 9007-36-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1331-1344

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK125823
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK116073
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001082
Pays : United States
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : R01 DK113586
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK076690
Pays : United States
Organisme : Wellcome Trust
ID : 212252/Z/18/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Références

Kidney Int. 2017 Oct;92(4):790-793
pubmed: 28938951
J Immunol. 1991 Feb 15;146(4):1265-70
pubmed: 1825108
Semin Immunol. 2019 Oct;45:101341
pubmed: 31757608
Kidney Int Rep. 2019 Jun 19;4(10):1387-1400
pubmed: 31701048
Kidney Int Rep. 2017 Nov 29;3(2):426-438
pubmed: 29725647
Clin J Am Soc Nephrol. 2010 Oct;5(10):1844-59
pubmed: 20595690
Immunol Rev. 2016 Nov;274(1):191-201
pubmed: 27782332
Kidney Int. 2017 Oct;92(4):953-963
pubmed: 28637589
PLoS One. 2013 Nov 18;8(11):e78617
pubmed: 24260121
Kidney Int. 2014 Apr;85(4):933-7
pubmed: 24067434
Front Immunol. 2021 Feb 25;12:615748
pubmed: 33732239
Front Immunol. 2017 Sep 19;8:1145
pubmed: 28974948
J Immunol. 2016 Feb 1;196(3):1355-65
pubmed: 26729803
Blood. 2007 Jul 1;110(1):228-36
pubmed: 17363730
Nat Rev Immunol. 2009 Oct;9(10):729-40
pubmed: 19730437
J Immunol. 2015 May 15;194(10):4963-73
pubmed: 25855355
Immunol Rev. 2016 Nov;274(1):152-171
pubmed: 27782321
Mol Immunol. 2010 Aug;47(13):2187-97
pubmed: 20580090
Mol Immunol. 2015 Sep;67(1):12-20
pubmed: 25824240
J Am Soc Nephrol. 2020 Feb;31(2):241-256
pubmed: 31980588
Ann Med. 2006;38(8):592-604
pubmed: 17438673
Front Immunol. 2018 Apr 24;9:848
pubmed: 29740447
Nat Genet. 2011 Mar 13;43(4):321-7
pubmed: 21399633
J Am Soc Nephrol. 2015 May;26(5):1195-204
pubmed: 25205734
PLoS Genet. 2012;8(6):e1002765
pubmed: 22737082
J Immunol. 2003 Feb 1;170(3):1517-23
pubmed: 12538716
PLoS One. 2016 Nov 4;11(11):e0166200
pubmed: 27814381
Am J Physiol Renal Physiol. 2007 Aug;293(2):F555-64
pubmed: 17522263
Biochem J. 1988 Jan 15;249(2):593-602
pubmed: 2963625
Front Immunol. 2020 Jun 19;11:1123
pubmed: 32636836
J Clin Invest. 2013 May;123(5):2218-30
pubmed: 23619360
Clin Exp Immunol. 2008 Jan;151(1):1-13
pubmed: 18081690
Kidney Int. 2005 Feb;67(2):524-30
pubmed: 15673300
Blood. 2009 Sep 17;114(12):2439-47
pubmed: 19528535
Nat Genet. 2002 Aug;31(4):424-8
pubmed: 12091909
Kidney Int. 2017 Oct;92(4):942-952
pubmed: 28673452
Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2897-902
pubmed: 21285368
J Am Soc Nephrol. 2018 Jan;29(1):240-249
pubmed: 28993505
Mol Immunol. 2015 Oct;67(2 Pt B):276-86
pubmed: 26163426
Mol Immunol. 2000 Jan-Feb;37(1-2):41-52
pubmed: 10781834
Kidney Int. 2011 Jul;80(2):165-73
pubmed: 21544060
Front Immunol. 2019 Mar 19;10:504
pubmed: 30941137
Front Immunol. 2014 Mar 31;5:126
pubmed: 24744754
J Immunol. 2018 Jan 1;200(1):316-326
pubmed: 29187587
J Immunol. 2006 Nov 1;177(9):6308-16
pubmed: 17056561
Lancet. 2010 Sep 4;376(9743):794-801
pubmed: 20800271
Am J Pathol. 2007 Jan;170(1):52-64
pubmed: 17200182
Eur J Immunol. 2018 May;48(5):791-802
pubmed: 29389016
J Clin Invest. 2020 Aug 3;130(8):4039-4054
pubmed: 32369457
J Mol Biol. 2008 Dec 5;384(1):137-50
pubmed: 18804116
Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4685-90
pubmed: 23487775
J Immunol. 2017 Jul 1;199(1):292-303
pubmed: 28533443
Immunogenetics. 2004 May;56(2):77-82
pubmed: 15118848
PLoS One. 2013 Apr 16;8(4):e60352
pubmed: 23613724

Auteurs

Brandon Renner (B)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Jennifer Laskowski (J)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Felix Poppelaars (F)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Viviana P Ferreira (VP)

Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

Judith Blaine (J)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Alexandra H Antonioli (AH)

Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, USA.

Jonathan P Hannan (JP)

Molecular Biophysics Program and Department of Biochemistry, University of Colorado, Boulder, Colorado, USA.

James M Kovacs (JM)

Department of Chemistry and Biochemistry, University of Colorado Springs, Colorado Springs, Colorado, USA.

Cees van Kooten (C)

Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands.

Zhiying You (Z)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Matthew C Pickering (MC)

Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, London, UK.

V Michael Holers (VM)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA.

Joshua M Thurman (JM)

Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, USA. Electronic address: Joshua.Thurman@cuanschutz.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH